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Background: Data from the Belgian Cystic Fibrosis Registry consistently show that in one of the seven reference centres, the prevalence of
Pseudomonas aeruginosa is half that observed at the national level.
Objectives: To report the characteristics of non-transplanted patients in this clinic at the end of 2003, with special focus on paediatric
patients. To describe and discuss our policy of inhaled antibiotic therapy.
Findings: The prevalence of P. aeruginosa among 116 patients is 20.7%. The chronic colonization rate is 19.8% but only 2.8% in patients
aged under 18 (n =72). Serologic data strongly support these results. Most paediatric patients (95%) are prescribed inhaled antibiotics, at least
on an intermittent basis but the mean number of days of intravenous antibiotic treatment is four times lower than in other CF children in
Belgium. 70% of children have an FEV190% predicted.
Discussion: We have reported a distinctly low rate of chronic colonization by P. aeruginosa in a cohort of CF children and suspect that a
strategy of early, often ?prophylacticX use of inhaled antibiotics, progressively implemented for over 15 years has substantially contributed to
these results. Given the major impact of chronic P. aeruginosa colonization on prognosis in CF, it is suggested that a large prospective study
of this approach is warranted.
D 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pseudomonas; Inhaled antibiotics; Prophylaxis1. Introduction
In cystic fibrosis (CF), the prevalence of the respiratory
pathogens may vary considerably from one country or
centre to another, probably reflecting differences in patient
monitoring, cohort isolation and antibiotic treatment policies
[1,2]. One of the aims of Cystic Fibrosis registries is to
identify differences in meaningful parameters between1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.04.001
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E-mail address: Lebecque@pedi.ucl.ac.be (P. Lebecque).centres as analysis of their determinants can result in
improvements in care [3].
Data from the Belgian CF registry [4] consistently
showed that in one of the seven Belgian cystic fibrosis
reference centres, the prevalence of PAwas particularly low,
around 25%, roughly half that observed at the national level.
This finding was accounted for by a very low prevalence of
PA in paediatric patients. Data also suggested that a specific,
often prophylactic, antibiotic treatment strategy might have
contributed to this particularity.
To the best of our knowledge, such a low prevalence of
PA in a CF clinic has not been reported previously. The aim
of this retrospective work is to describe the characteristics of
this clinic at the end of 2003 with special focus on the
paediatric patients, to specify the rate of chronic coloniza-5 (2006) 237 – 244ed by Elsevier B.V. All rights reserved.
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inhaled antibiotic therapy we progressively chose to
implement from 1986 onwards.Table 1





Number 116 72 44
Number of males (%) 58 (50) 37 (51.4) 21 (47.7)
Average age, in years (TS.D.) 16 (T10.8) 9 (T4.9) 27.5 (T7.7)
18 years old (%) 38
Median age at the time of
diagnosis, in months
7.4 4.3 24
Average period of time
between diagnosis and first
appointment at the St Luc
centre, in years (TS.D.)
4.4 (T6.7) 1.5 (T3) 9.1 (T8.3)
Median period of time between
diagnosis and first
appointment at the St Luc
centre, in years
0.4 0.1 8.4
% of patients having received
full time care at St Luc
<2 years after diagnosis
56.9 79.2 20.4
PSb (%) 19 15.3 25
Genotyped (%) 100 100 100
DF508/DF508 (%) 54.3 55.6 52.3
Meconial ileus (%) 16.4 20.8 9.1
Average FEV1 in %
pr. (TS.D.)
82 (T23%) 94 (T14.2) 67 (T22.8)
a Patients with lung-transplant are excluded.
b PS: pancreatic sufficient (no need for pancreatic enzyme substitution).2. Methods
A retrospective analysis of data from all patients
receiving full-time care at the UCL centre (Cliniques St
Luc-Brussels) in 2003 was undertaken, using the unit-
specific database, patients’ medical files and the Microbi-
ology Department’s database. Patients who had benefited
from a lung transplant were excluded. Criteria for the
diagnosis of cystic fibrosis met current consensus [5].
Since the clinic opened in 1986, standard practice with
these patients has been to get a respiratory culture performed
at every clinic visit, with no more than 3 months between
visits. Patients who do not expectorate spontaneously
undergo a full session of physiotherapy, after which either
expectorations are obtained or a deep pharyngeal aspiration
is performed, as recommended [6]. PA is isolated from
samples using standard microbiological methods [7]. As
soon as the bacteriological results are available, patients
always receive, along with their prescriptions, written
instructions detailing recommended antibiotic treatment
and reminding them to stop it if possible at least 4 days
before their next visit. Lung health is ascertained using the
surrogate marker of FEV1. Spirometry is routinely per-
formed at each consultation (Jaeger Masterscope, Wu¨rzburg,
Germany). From the age of 6, Knudson’s reference values
are used [8]. These have been criticized [9] but they permit
comparisons with both North American and Belgian
registers. PA prevalence was determined for each year
between 1999 and 2004 and defined as the percentage of
PA-positive cultures at the last visit of the year. Status of PA
infection was defined using Lee’s classification [10] which
takes into account the results of all cultures performed over
the previous 12 months. Each successive calendar month is
defined as: (1) PA+ (one or more PA-positive cultures that
month), (2) PA (all cultures that month negative for PA),
or (3) no culture performed that month. Patients are then
categorized as: (1) ‘‘Never’’ (never any PA growth), (2)
‘‘Free’’ (no growth of PA during the previous 12 months but
previously PA culture-positive, (3) ‘‘Intermittent’’ (50% or
less months when samples had been taken that were PA
culture-positive), or (4) ‘‘Chronic’’ (more than 50% of
months when samples had been taken that were PA culture-
positive).
At the end of 2004, PA serology was investigated in all
patients, using an Elisa technique to determine IgG levels
against a whole cell protein extract kindly provided by N.
Høiby (Rigshopitalet, Copenhagen, Denmark). High IgG
levels with this method are strongly associated with chronic
colonization [11]. When comparing its results and Lee’s
criteria in 162 CF patients at another clinic, a cut-off level of
17 AU was shown to predict chronic colonization by PAwith high sensitivity and specificity (88% and 96%
respectively) [12].
The modalities of inhaled antibiotic therapy prescribed to
patients at the end of 2003 have been summarized and
related to their bacteriological status. Annual data reports
from the Belgian Cystic Fibrosis Registry [4] enabled us to
compare prescribing patterns of therapeutic interventions at
St Luc with those at other centres. Additional data about
cohorting policies and intervention in the case of first PA
isolate were collected by the means of a brief questionnaire
sent to pulmonologists of the other Belgian centres.
Unpaired Student’s t-test and Chi-square or Fischer’s
Exact Test were used for statistical analysis. p values lower
than 0.05 were considered significant.3. Results
During the past 6 years, the prevalence of PA in CF
patients at St Luc has been low: 24.5% in 1999, 24.4% in
2000, 28.8% in 2001, 21.6% in 2002, 20.7% in 2003, 15%
in 2004 (n =130).
Table 1 summarizes the main characteristics of the 116
non-transplanted patients receiving full-time care at St Luc
at the end of 2003.
Table 2 summarizes bacteriological data in our clinic at
the end of 2003. According to Lee et al. [10], the rate of
chronic PA colonization is 19.8%. It attains 47.7% in adults,
but is only 2.8% in patients aged under 18, (2/72: one 16-
Table 2
Summary of bacteriological data of 116 non-transplanted patients at the end
of 2003
<18 years 18 years Whole
clinic
N 72 44 116
Chronic colonisation by PA
(according to Lee) (%)
2.8 47.7 19.8
Last visit
Normal flora or sterile (%) 80.6 18.2 56.9
PA (%) 2.8 50 20.7
Mucoid strain – 13.6 5.2
MSSA (%) 8.3 22.7 13.8
MRSA (%) 1.4 4.5 2.6
Hemophilus influenzae (%) 1.4 – 0.9
Aspergillus (%) 9.7 29.5 17.2
Stenotrophomonas maltophilia (%) 1.4 11.4 5.2
Achromobacter xylosoxidans (%) 1.4 6.8 2.6
BCC (%) – 2.3 0.9
B cenocepacia – – –
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the clinic and another 16-year-old patient who was lost at
follow-up for 15 months and was colonized on his return to
the centre). Among paediatric patients, PA antibodies levels
suggestive of chronic colonisation were only found in these
2 patients. Mean (TS.D.) values (AU) for ‘‘chronic’’,
‘‘intermittent’’, ‘‘free’’ and ‘‘never’’ patients were 25T8.5,
2T3.1, 2.8T3.7 and 1.3T2.5, respectively. Chronic coloni-
zation by PA in adult patients was often established when
they first attended the clinic (11/21, 52.3%).
In contrast, PA prevalence at the national level was 48%
in 2000. The median age of patients at St Luc (14.6 years)
(2003) is comparable to that at national level (14.7) (2001),
as are the proportion of adult patients (38% vs. 39.6%), the
proportion of patients homozygous for the DF508 mutation
(54.3% vs. 55.4%), the meconial ileus rate (16.4% vs.
15.6%), the average number of annual outpatient visits by a
pulmonologist (5.2) and the rate of DNase prescription
(41% vs. 49.4%). The proportion of PS patients is higher at
St Luc than in the register as a whole (19% vs. 11.4%).
Inhaled steroids (54% vs. 35.1%) and bronchodilators (92%
vs. 59.4%) were more often prescribed at St Luc. More
strikingly, although PA prevalence was half at St Luc,Table 3
Modalities of inhaled antibiotic therapy prescribed for the 72 paediatric patients at
Lee’s classification Inhaled antibiotic therapy
No Intermittent
n (%) n (%) n (%)
Chronic 2 (2.8%) 0 0
Intermittent 5 (6.9%) 0 0
Free 27 (37.5%) 2 (7.4%) 3 (11.1%)
Never 38 (52.8%) 2 (5.3%) 10 (26.3%)
Total 72 (100%) 4 (5.5%) 13 (18.1%)
a In many cases preceded by a long period of intermittent inhaled antibiotic the
b As soon as a patient was regarded as chronically colonized, continuous inhalinhaled antibiotics were more often prescribed at the last
visit of the year (89% vs. 43.7%).
Detailed data concerning the mean number of days of
intravenous antibiotic treatment in CF children were
available in the Belgian registry for 2003 and 2002. This
number was significantly lower at St Luc (1.34 and 1.25,
respectively) than for the children followed elsewhere (5.15
and 5.4, respectively, p <0.001).
At the end of 2003, the average FEV1 (TS.D.) of patients
aged between 6 and under 18 is 94% predicted (T14.7).
FEV1 is 90% predicted in 70% of these children, 40–
69% predicted in 6.2%. No child has an FEV1<40%
predicted.
Table 3 describes the modalities of inhaled antibiotic
therapy prescribed to the 72 paediatric patients at their last
visit in 2003. When continuous inhaled antibiotic therapy is
prescribed, the period of time during which this treatment is
taken is specified. Intermittent inhaled therapy almost
always refers to a treatment to be initiated for 3 weeks
(usually together with oral amoxiclav) in case of other than
trivial presumed viral upper airway infection.
At the end of 2003, 94.4% of patients aged under 18
were on intermittent or continuous inhaled antibiotic
therapy. Inhaled antiobiotics prescribed to paediatric
patients were as follows: TOBI (2/68: 2.9%), Colimycin
alone (only if Pseudomonas aeruginosa had been isolated
previously, 11/68: 16.2%), injectable forms of tobramycin
(28/68: 41.2%) and Amikacin (27/68: 39.7%). In all cases,
an inhaled bronchodilator was also prescribed. Except in the
case of TOBI, antibiotics and salbutamol were mixed which
has been shown to be acceptable [13] and saved nebuliza-
tion time. The daily dose of tobramycin (or amikacin)
prescribed was low in comparison with TOBI, around 5–10
(15–30) mg/kg/day (Table 4).
Most children (68%) used an ultrasonic nebulizer (devices
without direct contact between crystal and drugs –
mainly Systam brand). The others used a mechanical
compressor (mainly Pari Turbo boy with Pari LC+nebulizer
or Porta Neb+Ventsream nebulizer). Use of a mouthpiece
(rather than a facemask) was repeatedly encouraged from
age 4.
Strict segregation of patients on a bacteriological basis
including in the outpatient setting was applied in 5 of the 6the end of 2003, based on their bacteriological status according to Lee et al.
Continuous inhaled antibiotic therapya
Continuous Duration in years (meanTS.D.) Range
n (%)
2 (100%) b
5 (100%) 2T1.9 (0.4–4.2)
22 (81.5%) 3.2T1.4 (1.1–6)
26 (68.4%) 2.4T1.3 (0.9–5.6)
55 (76.4%)
rapy.
ed antibiotic therapy was always prescribed.
Table 4
Usual dosages of prophylactic inhaled antibiotics at St Luc
Tobramycin
(80 mg/2 ml)
4–8 kg 20 mg twice a day 5–10 mg/kg/day
8–15 kg 40 mg twice a day 5.3–10 mg/kg/day
15–30 kg 80 mg twice a day 5.3–10.6 mg/kg/day
Amikacin
(500 mg/2 ml)
30–50 kg 250 mg twice a day 10–16.7 mg/kg/day
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In none of the 5 largest centres was intravenous antibiotic
treatment prescribed as the first-line intervention in the case
of first isolation of PA.4. Discussion
The PA prevalence reported here is particularly low, half
that observed at the national level which is itself in keeping
with current data from other European countries and US
[14–17]. More importantly, the rate of respiratory chronic
colonization by this pathogen is very low in paediatric
patients, almost 6 times less than that recently reported
using the same definition by Lee et al. [18]. The interest of
these data lies in the well-established negative impact of
chronic PA colonization on prognosis in cystic fibrosis
patients. Chronic PA colonization is associated with a lower
FEV1 in childhood [19], an accelerated rate of decline of
FEV1 [20–22] and a shorter median life expectancy
[22,23].
Preventing PA chronic colonization is now considered
the most important challenge for the CF clinician, as it
frequently determines the patient’s future quality of life and
long-term survival as well as the cost of care [7,24,25].
Early treatment at the time of the first PA colonization
greatly reduces the incidence of chronic colonization
[18,26–31]. Unfortunately, there is no current consensus
about the optimal eradication regimen and the failure rate of
this approach has been estimated around 15–27%
[18,28,31]. Moreover, even when it succeeds, a different
strain of PA will often be isolated within 12 months [32].
It has recently been suggested that early ?prophylacticX
administration of inhaled antibiotics may be beneficial [33].
In a preliminary study initiated in 1986, Heinzl et al.
prescribed long-term prophylactic gentamycin inhalation for
a cumulative period of 132 years in young CF children at
special risk of PA-acquisition. The treatment was well
tolerated and not associated with any PA-acquisition.
Nevertheless, a recent European consensus stated that given
the lack of studies, the burden of this approach and the
effectiveness of early antibiotic treatment when PA is first
isolated, it could not be currently recommended [3].
Central to the discussion is the definition of chronic PA
colonization which remains debated. We chose to adopt
Lee’s definition [10] for several reasons. It has beenvalidated; it does not involve antibodies dosages which
are not always available and whose interpretation is
critically dependent on methodological options; it is based
on the results of all the cultures performed over the previous
12 months, then appearing especially meaningful for
relevant practical issues such as patient segregation.
Among paediatric patients, high levels of specific serum
antibodies against PA were only found in the two patients
classified as chronically colonized. This finding concurs
with previous data [11]. Using this definition, Lee et al.
recently described a fall from 24% to 18% in the rate of
chronic PA colonization in their paediatric population
between 1990 and 2000 [18]. Like in Denmark, close
microbiological monitoring permitting early aggressive
treatment of the first isolates of PA and patient segregation
according to bacteriological status were regarded as key-
factors contributing to such improvement [18,24,34]. Yet
this rate of 18% remains well above the rate reported at the
St Luc Cystic Fibrosis Reference Centre.
At their last hospital appointment in 2003, the FEV1 of
70% of paediatric patients was 90% of the predicted
value. In Belgium, the corresponding rate in the national
registry was 44.8% in 2001 [4]. In the USA, where the
average of the best value per quarter is used, the rate
attained 45.2 in 2003 [17]. Such encouraging results are to
be expected when very few patients are chronically
colonized by PA but many other factors could be involved.
Detailed comparison with data from other centres in
Belgium using the 2000 cystic fibrosis registry proved to be
difficult and has not been attempted. One reason for this is
that some data are missing in the registry. For example,
while bacteriological data are available for all patients
treated at St Luc, this was not the case for 17.7% of other
patients in the registry. In the registry, information on socio-
economic status is very limited which makes it impossible
to exclude a selection bias. The impact of socio-economic
status on prognosis has been well documented in the USA
[35] but the quality of the Belgian national healthcare
system, based on solidarity, is likely to greatly reduce it. In
addition, the register does not enable us to assess the
implementation of cohort isolation in the Belgian centres.
Such a policy has been strict from the start at St Luc. The
questionnaire sent to the pulmonologists of all other Belgian
centres confirmed that they implemented it later for
outpatients, which may have contributed to the difference
in PA prevalence [24]. Nevertheless other centres around the
world have had strict policies on this point for a long time
and segregation alone cannot explain the difference in PA
prevalence [18].
The proportion of PS patients is higher at the St Luc
(15%<18 years, 19% for the whole clinic) than in the
registry (11.4%). This can be explained by the fact that some
patients with intermediate sweat chloride levels were
diagnosed in the context of a large study [36] and by a
recruitment bias related to an expertise in nasal PD
measurements [37]. Chronic PA colonization seems to
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for the difference observed.
The low prevalence of PA in children at St Luc might be
expected to be associated with a better clinical outcome. As
mentioned above, data from the 2003 registry do not yet
permit a comparison between centres. Fortunately, data
collected for an other ongoing belgian (multicentric) study
provide this information and are consistent with the
expectations. They concern all the 6–18 years old children
followed in the 6 main CF centres in Belgium at the end of
the year 2003 for whom at least one spirometry and one
respiratory culture were available for this year. PA preva-
lence was 5% at St Luc and 28% for the 178 other children
( p <0.01). The mean FEV1 and WFH were significantly
higher at St Luc (FEV1: 95%T15 vs. 83%T22, p <0.01;
WFH: 100%T11 vs. 93%T11, p <0.01).
A significant reduction of the mean number of days of
intravenous antibiotic treatment was observed in CF
children at St Luc, which is important for several reasons:
(1) it demonstrates that the low prevalence of PA in these
patients is not due to more frequent IV treatments; (2) as the
difference is very significant in comparison with other
belgian CF children and as all but one centres do not
prescribe IV AB as the first line treatment of initial
colonization by Ps A (see T1R1), this suggest a reduction
in the number of exacerbations comparable to that repeat-
edly reported in controlled studies about the use of inhaled
Tobramycin in colonized patients; (3) this reduction of IV
AB treatment can be expected to be associated with an
increased quality of life and could be a counterpart to the
burden of the treatment; (4) as in 2002 and 2003, 80% and
75% of these days took place in the hospital setting, this
reduction is associated with decreased hospital-bed utiliza-
tion and associated costs.
Specific to our centre in Belgium at this time was a
policy of early, often ?prophylacticX, inhaled antibiotic
therapy progressively implemented for over 15 years.
Gradually better structured, this policy is to some extent
similar to the experience reported by Heinzl et al. [33]. We
suspect it to have greatly contributed to the singularity of the
bacteriological results obtained at St Luc.
The St Luc Cystic Fibrosis clinic was launched in 1986.
All patients are seen by the same paediatric pulmonologist
(PL). From the outset, standard practice for patients
receiving care at our Centre involved having sputum or
pharyngeal aspirates taken at every hospital appointment,
with no more than 3 months between visits, early treatment
of first PA isolate, contacts between patients actively
discouraged, strict segregation of patients on a bacteriolog-
ical basis both in the outpatient setting and during
hospitalization, dedicated respiratory function equipment
with no closed circuits, mouthpieces and connectors that are
discarded or sterilized after each use, chest physiotherapy as
from diagnosis of the disease.
Eradication regimens prescribed to patients after their
first growth of PA evolved over time. Inhaled colomycin[26] and then oral ciprofloxacin too [27] were initially
prescribed for at least 3 weeks. If the culture remained
positive, the treatment was repeated or, in rare cases,
intravenous antibiotic therapy prescribed. Before the bene-
fits of continuing this initial treatment for 3 months were
demonstrated [28], the inhaled antibiotic therapy was often
extended to 3–6 months or more, particularly if it was not
the first time PA had been isolated. It sometimes even
remained continuous, especially with patients whose com-
pliance was felt to be less reliable or when a clinical benefit
seemed evident, as evidenced by a decrease in or
disappearance of chronic cough. Evidence that chronic PA
colonization could not be prevented in almost 20% of cases
where the patient received conventional regimens of early
antibiotic therapy has strengthened this attitude [18,28,31].
Recently, the effectiveness of long-term aminoglycoside
nebulization to prevent chronic PA colonization has been
documented [29,30].
Moreover, an increasing number of patients in whom PA
had never been isolated were prescribed temporary or
sometimes long-term and then continuous ‘‘prophylactic’’
treatment. As in Heinzl’s study [33], most of them were
infants or children presenting risk factors for acquisition of
PA as described in the literature [39–42]: meconium ileus
surgery, repeated or long-term hospitalisation especially
early in life, admission to an intensive care unit, persistence
of Staphylococcus aureus in the respiratory secretions
despite oral antibiotic therapy. Prescribing an antibiotic
active against Hemophilus influenzae when patients have a
cold is a common practice with CF [7]. When doing so, we
always added intermittent use of inhaled antibiotics, given
the evidence that respiratory virus infections may pave the
way for PA [43]. Finally, inhaled antibiotic therapy has
sometimes been proposed when a cough was observed on a
daily basis, after having looked for and treated when
indicated gastro-oesophageal reflux and bronchial hyperre-
activity. While not entirely systematic, this approach has
been increasingly adopted as data accumulated confirming
the good tolerance of long-term inhaled antibiotic therapy
[44] and its effectiveness was observed.
Given the lack of prospective studies, this policy might
be considered as intuitive at best. Yet, a number of
theoretical considerations can make early use of inhaled
antibiotics attractive. It is now acknowledged that PA
infection in CF occurs much earlier than previously believed
and that the sensitivity of even rigorous bacteriological
monitoring might not be optimal for early detection of the
presence of this pathogen [42,45,46]. Early treatment is
crucial to avoid irreversible chronic colonization which
worsens prognosis though its failure rate is far from
negligible. Aminoglycosides are also effective against other
pathogens often encountered in CF (e.g. S. aureus and H.
influenzae). Delivery of inhaled medications can be
predicted to be better when airways damage is minimal.
Airways inflammation in CF is usually believed to be
secondary to infection so inhaled antibiotics could to some
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currently available for this disease. It is paradoxical that the
possible benefit of prophylactic antibiotic therapy to target
this pathogen has barely been studied so far, contrary to
what has been the case with S. aureus.
The currently recommended daily dose of TOBI is the
same for an adult and a 6-year-old child. In comparison, the
daily dose of tobramycin (or amikacin) we prescribed was
2–3 times lower, around 5–10 (15–30) mg/kg/day.
Relating dose to weight in this way does not make much
sense, because penetration of inhaled medication into the
lungs does not vary linearly with weight or age [47].
Caution is warranted however with infants and young
children for who only limited data on systemic absorption
are available. Serum creatinine was measured at least once
per year and remained normal in all cases. Audiometry was
not performed systematically because available data in the
literature seem very reassuring in this respect. It should also
be realized that these small doses were delivered in a rather
inefficient way because a standard unvented nebulizer was
used and young children had to use a facemask. Even when
a mouthpiece is used, such nebulizers are expected to
deposit only about 10% of the dose in the lungs [48] while
the Pari LC Jet which is used with TOBI would deliver
approximately 15% of the dose [49] and the more modern
LC Star could deliver as much as 35% to the lungs [50]. In
the Heinzl’s study, 12 young children received continuous
higher doses of inhaled gentamycin (80 mg twice daily <12
months, 120 mg twice daily >12 months) for more than 6
years (6–12 years), without evidence of hearing or renal
impairment [33]. Yet, wide-scale very long term safety data
are currently lacking.
Danish authors have recently reported very encouraging
results using a more conservative approach where monthly
bacteriological controls and regular measurements of the
antibody response hopefully allowed optimal early use of
oral ciprofloxacin and inhaled colistin for periods of 3
weeks or 3 months [51]. This treatment however has often
to be repeated and such close follow-up has been considered
unrealistic in many countries [52].
One theoretical risk of prophylactic inhalation of amino-
glycosides is that it could lead to the emergence of resistant
strains of PA which we have not observed. In fact,
characteristics of PA isolates initially infecting the CF
airway are known to be more favourable to eradication with
appropriate antibiotic therapy [45,53,54]. They are usually
nonmucoid, highly susceptible to antibiotics and present in
lower density than in established infections, so the
probability of mutations is also lower.
There is concern that prolonged intermittent treatment
with inhaled tobramycin might increase isolation of
emergent pathogens and especially fungal organisms [55]
but this was not observed in this small sample of paediatric
patients most of whom had normal spirometry.
Inhaled antibiotics are a time-consuming treatment.
Compliance was not investigated but seems clearly sup-ported by the bacteriological results. In our clinic, a single
pulmonologist personally cares for all the patients while 2–
6 physicians are involved in the respiratory care of CF
patients in the other Belgian centres. Conceivably, this
unusual continuity of care may have facilitated coherence of
attitudes and perhaps favoured adherence to treatment.
There is no reason to suspect that an excess mortality of
chronically colonised children at St Luc could have
contributed to our results. Between 1986 and 2003, only 4
CF children treated at the clinic died. When they first
attended the clinic, three of them were already chronically
colonised by PA. They were 11.2, 7.2 and 7.1 years old at
this time and corresponding values for FEV1 (% predicted)
were 48%, 27% and 21%, respectively. The fourth child also
suffered from autism. He died when he was 17 from hepatic
failure, liver transplant being contraindicated. Although
numbers are small, the overall mortality rate of CF patients
at St Luc between 1999 and 2002 is comparable to that
recorded at the national level in the registry (5 patients/467
patient years: 1.07% vs. 35/2.718 patient years: 1.28%),
with a median age at death of 30 years (vs. 23 years in the
registry).
We made no attempt to estimate the cost/benefit ratio of
our approach. Inhaled antibiotics are obviously expensive,
even at relatively low doses. On the other hand, Baumann et
al. [25] recently reported that in a paediatric CF clinic, the
annual costs of patients with chronic PA infection were
more than three times higher than those of uninfected
patients.
In this descriptive retrospective study, we have reported a
particularly low rate of chronic colonization by PA in a
cohort of paediatric CF patients. We have not however
demonstrated that it is accounted for by our strategy of early,
often ?prophylacticX use of inhaled antibiotics, progressive-
ly implemented for over 15 years although this is an
attractive hypothesis. In fact, current objective data are well
reflected by a recent statement from a european consensus
about early intervention and prevention of lung disease in
cystic fibrosis: this approach has not been well studied and
is not currently recommended (DIII) [3].
Nevertheless, in our experience, it seems to be very
effective. Given the major impact of chronic PA coloniza-
tion on CF prognosis, it is suggested that a large prospective
study of this approach is warranted, not only in order to
assess its efficacy and confirm long-term safety but also in
order to determine its relative impact with respect to other
factors and its potential cost-effectiveness.Acknowledgments
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